Lv11
70 积分 2025-06-12 加入
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
9小时前
待确认
Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer
11小时前
已完结
Cellular neighborhoods in cancer
1个月前
已完结
Tumour promotion through the lens of evolution
1个月前
已完结
Minimal residual disease as a target for liquid biopsy in patients with solid tumours
2个月前
已完结
A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy for localized triple-negative breast cancer (TNBC) (PLANeT trial—Pembrolizumab Low dose in Addition to NACT in TNBC)
2个月前
已完结
Optimizing the dose and schedule of immune checkpoint inhibitors in cancer to allow global access
2个月前
已完结
Reduced/No Dexamethasone With Netupitant/Palonosetron and Olanzapine for Chemotherapy‑Induced Nausea/Vomiting in Highly Emetogenic Chemotherapy: Phase III Noninferiority Trial
2个月前
已完结
Combination cancer immunotherapies tailored to the tumour microenvironment
3个月前
已完结
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
3个月前
已完结
皖公网安备34019202002308
